Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

610 ARTÍCULOS , VIENDO DEL 586 AL 600

Neuropsychiatric Symptoms Present Differently in Individuals with Different High-Risk States of Dementia

Keng A, Kapustin D, Ma C, Bingham KS, Fischer CE, Mah L, Gallagher D, Butters MA, Bowie CR, Voineskos AN, Graff-Guerrero A, Flint AJ, Herrmann N, Pollock BG, Mulsant BH, Rajji TK, Kumar S.

Dement Geriatr Cogn Disord. 2026;55(1):49-60. doi: 10.1159/000547061. Epub 2025 Jun 25.

IL-24 ameliorates cognitive dysfunction via the inhibition PERK-eIF2α Signaling pathway in Alzheimer's disease

Du Y, Zheng X, Yue X, Fu P, Diao J, Zhang A, Cheng H, Yang H, Bi J, Zhou Q, Wang P.

Int Immunopharmacol. 2026 Jan 15;169:116039. doi: 10.1016/j.intimp.2025.116039. Epub 2025 Dec 18.

Long-term cognitive outcomes following post-TAVR stroke: A propensity-matched analysis from the TriNetX network

Bolaji O, Nor M, Naeem A, Bahar AR, Basit J, Jahan S, Ouedraogo F, Lawrence I, Oseni A, Alraies MC.

Int J Cardiol. 2026 Jan 1;442:133804. doi: 10.1016/j.ijcard.2025.133804. Epub 2025 Aug 19.

Anthocyanin supplementation in adults at risk for dementia: a randomized controlled trial on its cardiometabolic and anti-inflammatory biomarker effects

Borda MG, Ramírez-Vélez R, Botero-Rodriguez F, Patricio-Baldera J, de Lucia C, Pola I, Barreto GE, Khalifa K, Bergland AK, Kivipelto M, Cederholm T, Zetterberg H, Ashton NJ, Ballard C, Siow R, Aarsland D; NJ FINGER.

Geroscience. 2026 Feb;48(1):563-576. doi: 10.1007/s11357-025-01669-8. Epub 2025 May 2.

Exercise prescriptions for older adults with different degrees of cognitive impairment: A dose-response network meta-analysis

Zang W, Fang M, Xiao N, Wu J, Zhang Q, Mao X.

Clin Rehabil. 2026 Feb;40(2):154-170. doi: 10.1177/02692155251385219. Epub 2025 Oct 14.

Dialysis modality and cognitive outcomes in chronic kidney disease: a systematic review and meta-analysis

Malik A, Mansour HRK, Kundur SP, Hunjan A, Zaheer R.

Clin Exp Nephrol. 2026 Mar;30(3):408-423. doi: 10.1007/s10157-025-02798-2. Epub 2025 Dec 1.

Esports Interventions for Dementia and Mild Cognitive Impairment: A Rapid Scoping Review

Okuyama K, Isaji Y, Tanaka K, Suzuki K, Kurasawa Y, Kaneko T, Kitagawa T.

Dement Geriatr Cogn Disord. 2026;55(2):161-171. doi: 10.1159/000547651. Epub 2025 Jul 30.

Delirium: a modifiable risk factor for dementia

van Munster BC, Strijkert F, Trzpis M, Slooter AJC, van den Boogaard M, Ottens TH; DELIER-NL: the Dutch Interdisciplinary Delirium Network.

Eur Geriatr Med. 2026 Apr;17(2):549-552. doi: 10.1007/s41999-025-01360-3. Epub 2025 Nov 21.

Mind Your Mouth: Impact of Oral Bacteria on Alzheimer's Disease

Mohammed AI, Mohammed AI, Reynolds E.

J Oral Pathol Med. 2026 Jan;55(1):1-6. doi: 10.1111/jop.70111. Epub 2025 Dec 23.

Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders

Sabbagh MN, Cummings JL, Ballard C, van der Flier WM, Heneka MT, Holst JJ, Knudsen LB, Salloway S, Tansey MG, Drucker DJ.

Nat Aging. 2026 Jan;6(1):56-67. doi: 10.1038/s43587-025-01029-3. Epub 2025 Dec 19.

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease

Rosenberg PB, Amjad H, Burhanullah H, Nowrangi M, Vandrey R, Pierre MJ, Outen JD, Schultz M, Marano C, Agronin M, Wilkins JM, Harper D, Laffaye T, Reardon E, Turner K, Ozonsi R, Drury M, Nguyen A, Hasoğlu T, Cromwell J, Leoutsakos JM, Forester BP.

Am J Geriatr Psychiatry. 2026 Feb;34(2):167-179. doi: 10.1016/j.jagp.2025.10.011. Epub 2025 Nov 10.

Neuropsychiatric signatures across the Alzheimer's disease continuum in Down syndrome and sporadic forms: A biomarker-driven comparison

Botella M, Estanga A, Ros N, Saldias J, Cañada M, García-Sebastián M, Larrea JÁ, Echeverria M, Garrido A, Altuna M.

J Alzheimers Dis. 2026 Feb;109(3):1508-1519. doi: 10.1177/13872877251407121. Epub 2025 Dec 30.

Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment

Naeshiro Y, Kitani-Morii F, Kasai T, Tanaka E, Kobayashi F, Ohara T.

Intern Med. 2026 Apr 1;65(7):1056-1060. doi: 10.2169/internalmedicine.6070-25. Epub 2025 Aug 21.

Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer's disease - an exploratory post hoc analysis

Wang HJ, Ruthirakuhan M, Andreazza AC, Beroncal EL, Black SE, Gallagher D, Herrmann N, Kiss A, Verhoeff NPLG, Lanctôt KL.

Neurodegener Dis Manag. 2026 Apr-Jun;16(3):263-272. doi: 10.1080/17582024.2025.2587549. Epub 2025 Nov 11.

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials

Abushakra S, Doraiswamy PM, Hey JA, Tosun D, Barkhof F, Barakos J, Petrella J, Kesslak JP, Power A, Sabbagh M, Porsteinsson A, Cohen S, Gauthier S, Ritchie C, Watson D, McSweeney E, Boada M, Liang E, Bracoud L, McLaine R, Flint S, Schaefer JF, Yu J, Bray M, Hendrix S, Dickson S, Durrant A, Albayrak A, Tolar M.

CNS Drugs. 2026 Feb;40(2):199-214. doi: 10.1007/s40263-025-01251-y. Epub 2025 Dec 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias